Research letter
How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials

https://doi.org/10.1016/j.jaad.2017.05.032Get rights and content

First page preview

First page preview
Click to open first page preview

References (4)

There are more references available in the full text version of this article.

Cited by (3)

Funding sources: Supported in part by a National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin grant (K24 AR064310) to Dr Gelfand.

Conflicts of interest: Dr Wu received research funding from AbbVie Inc, Amgen, Boehringer Ingelheim, Dermira, Eli Lilly and Company, Janssen Pharmaceutical, Novartis, Regeneron, and Sun Pharmaceutical Industries Ltd; Dr Wu is a consultant for AbbVie Inc, Amgen, Celgene, Dermira, Eli Lilly and Company, LEO Pharma, Regeneron, and Valeant Pharmaceuticals International Inc. In the previous and foreseeable 12 months, Dr Strober serves as a consultant and advisor for AbbVie Inc, Amgen, AstraZeneca, Celgene, Dermira, Janssen Pharmaceutical, Leo Pharma, Eli Lilly and Company, Cutanea-Maruho, Medac, Novartis, Pfizer, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, UCB Inc, and Valeant receiving honoraria; received grants (paid to the University of Connecticut and not to Dr Strober himself) from AbbVie Inc, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Eli Lilly and Company, Janssen Pharmaceuticals, Merck & Co, Sun Pharmaceutical Industries Ltd, Celgene; and serves as a scientific director for Corrona Psoriasis Registry receiving a consulting fee. In the previous 12 months, Dr Gelfand served as a consultant for Coherus BioSciences, Janssen Biologics (formerly Centocor), Merck & Co, Novartis Pharmaceuticals Corporation, Valeant Pharmaceuticals, Sanofi, and Pfizer Inc receiving honoraria; received research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc, Janssen Pharmaceuticals, Novartis Corp, Regeneron, Sanofi, Celgene, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Abbvie Inc. Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. No other conflicts of interest were declared.

Reprints not available from the authors.

View full text